Apollo Medical Holdings Reports 46% Revenue Increase For 2018
Apollo Medical Holdings Reports 46% Revenue Increase For 2018
PR Newswire
ALHAMBRA, Calif. and GLENDALE, Calif., March 18, 2019
ALHAMBRA, Calif. and GLENDALE, Calif., March 18, 2019 /PRNewswire/ -- Apollo Medical Holdings, Inc. ("ApolloMed" or the "Company") (NASDAQ: AMEH), an integrated population health management company, today announced its consolidated 2018 consolidated financial results for the year ended December 31, 2018.
Financial Highlights for the Year Ended December 31, 2018 compared to the Year Ended December 31, 2017:
- Total revenue of $519.9 million for the year ended December 31, 2018 as compared to total revenue of $356.4 million for the year ended December 31, 2017, an increase of 46%.
- Income from operations of $88.4 million for the year ended December 31, 2018 as compared to $35.1 million for the year ended December 31, 2017, an increase of 152%.
- Net income attributable to Apollo Medical Holdings, Inc. of $10.8 million for the year ended December 31, 2018 as compared to $25.8 million for the year ended December 31, 2017, a decrease of 58%.
- As of December 31, 2018, the Company had total assets of $513.0 million, including cash and cash equivalents of $106.9 million.
"2018 was a year of exceptional growth, and we are proud of the entire ApolloMed team," stated Eric Chin, Chief Financial Officer of ApolloMed. "We enter 2019 with a strong foundation and good momentum and will continue to execute on our strategies for long-term success."
"We made significant investments in talent and infrastructure in 2018 which impacted our near-term profitability, but which we believe positions us very well for long-term growth," stated Warren Hosseinion, M.D., Co-Chief Executive Officer of ApolloMed. "We believe our population health management platform is central to the shift of the healthcare industry from fee-for-service payments to value-based reimbursements."
"We are considering accessing the credit and equity markets this year, and deploying this capital to further accelerate our growth," stated Thomas Lam, M.D., Co-Chief Executive Officer of ApolloMed. "Our management team has identified a pipeline of acquisitions and is actively evaluating several potential acquisitions."
"National health spending, which was approximately $3.6 trillion in 2018, is projected to reach nearly $6 trillion by 2027. Approximately 10,000 people are enrolling in Medicare every day, and this is expected to continue until 2030," stated Kenneth Sim, M.D., Executive Chairman of ApolloMed. "We believe that the Company is very well-positioned to benefit from these key economic and demographic factors. Our team is more energized than ever and we are confident in our prospects to create shareholder value through successful execution of our strategies."
For more details on ApolloMed's December 31, 2018 year end results, please refer to the Company's Annual Report on Form 10-K to be filed with the U.S. Securities Exchange Commission ("SEC") and accessible at www.sec.gov.
Apollo Medical Holdings, Inc. | ||||||||
Consolidated Balance Sheets (unaudited) | ||||||||
December 31, | 2018 | 2017 | ||||||
Assets | ||||||||
Current assets | ||||||||
Cash and cash equivalents | $ | 106,891,503 | $ | 99,749,199 | ||||
Restricted cash | - | 18,005,661 | ||||||
Investment in marketable securities | 1,127,102 | 1,143,095 | ||||||
Receivables, net | 7,734,631 | 7,602,812 | ||||||
Receivables, net – related parties | 48,721,325 | 12,514,492 | ||||||
Prepaid expenses and other current assets | 8,388,231 | 5,144,303 | ||||||
Total current assets | 172,862,792 | 144,159,562 | ||||||
Noncurrent assets | ||||||||
Land, property and equipment, net | 12,721,082 | 13,814,306 | ||||||
Intangible assets, net | 86,875,883 | 103,533,558 | ||||||
Goodwill | 185,805,880 | 189,847,202 | ||||||
Loans receivable – related parties | 17,500,000 | 15,000,000 | ||||||
Investments in other entities – equity method | 34,876,980 | 21,903,524 | ||||||
Investment in a privately held entity that does not report net asset value per share | 405,000 | - | ||||||
Restricted cash – long-term | 745,470 | 745,235 | ||||||
Other assets | 1,205,962 | 1,632,406 | ||||||
Total noncurrent assets | 340,136,257 | 346,476,231 | ||||||
Total assets | $ | 512,999,049 | $ | 490,635,793 | ||||
Apollo Medical Holdings, Inc. | ||||||||
Consolidated Balance Sheets (unaudited) (Continued) | ||||||||
December 31, | 2018 | 2017 | ||||||
Liabilities, Mezzanine Equity and Shareholders' Equity | ||||||||
Current liabilities | ||||||||
Lines of credit – related party | $ | - | $ | 5,025,000 | ||||
Accounts payable and accrued expenses | 25,075,489 | 13,279,620 | ||||||
Provider incentives payable | - | 21,500,000 | ||||||
Fiduciary accounts payable | 1,538,598 | 2,017,437 | ||||||
Medical liabilities | 33,641,701 | 63,972,318 | ||||||
Income taxes payable | 11,621,861 | 3,198,495 | ||||||
Bank loan, short-term | 40,257 | 510,391 | ||||||
Capital lease obligations | 101,741 | 98,738 | ||||||
Total current liabilities | 72,019,647 | 109,601,999 | ||||||
Noncurrent liabilities | ||||||||
Lines of credit - related party | 13,000,000 | - | ||||||
Deferred tax liability | 19,615,935 | 24,916,598 | ||||||
Liability for unissued equity shares | 1,185,025 | 1,185,025 | ||||||
Dividend payable | - | 18,000,000 | ||||||
Capital lease obligations, net of current portion | 517,261 | 619,001 | ||||||
Total noncurrent liabilities | 34,318,221 | 44,720,624 | ||||||
Total liabilities | 106,337,868 | 154,322,623 | ||||||
Commitments and Contingencies (Note 14) | ||||||||
Mezzanine equity | ||||||||
Noncontrolling interest in Allied Pacific of California IPA | 225,117,029 | 172,129,744 | ||||||
Shareholders' equity | ||||||||
Series A Preferred stock, par value $0.001; 5,000,000 shares authorized (inclusive of Series B Preferred stock); 1,111,111 issued and zero outstanding | - | - | ||||||
Series B Preferred stock, par value $0.001; 5,000,000 shares authorized (inclusive of Series A Preferred stock); 555,555 issued and zero outstanding | - | - | ||||||
Common stock, par value $0.001; 100,000,000 shares authorized, 34,578,040 and 32,304,876 shares outstanding, excluding 1,850,603 and 1,682,110 Treasury shares, at December 31, 2018 and 2017, respectively | 34,578 | 32,305 | ||||||
Additional paid-in capital | 162,723,051 | 158,181,192 | ||||||
Retained earnings | 17,788,203 | 1,734,531 | ||||||
180,545,832 | 159,948,028 | |||||||
Noncontrolling interest | 998,320 | 4,235,398 | ||||||
Total shareholders' equity | 181,544,152 | 164,183,426 | ||||||
Total liabilities, mezzanine equity and shareholders' equity | $ | 512,999,049 | $ | 490,635,793 | ||||
Apollo Medical Holdings, Inc. | ||||||||
Consolidated Statements of Income (unaudited) | ||||||||
Years ended December 31, | 2018 | 2017 | ||||||
Revenue | ||||||||
Capitation, net | $ | 344,307,058 | $ | 272,921,240 | ||||
Risk pool settlements and incentives | 100,927,841 | 44,598,373 | ||||||
Management fee income | 49,742,755 | 26,983,695 | ||||||
Fee-for-service, net | 19,703,999 | 7,449,249 | ||||||
Other income | 5,226,099 | 4,403,373 | ||||||
Total revenue | 519,907,752 | 356,355,930 | ||||||
Operating expenses | ||||||||
Cost of services | 361,132,111 | 273,453,287 | ||||||
General and administrative expenses | 43,353,787 | 26,249,532 | ||||||
Depreciation and amortization | 19,303,179 | 19,075,353 | ||||||
Provision for doubtful accounts | 3,887,647 | - | ||||||
Impairment of goodwill and intangible assets | 3,798,866 | 2,431,791 | ||||||
Total expenses | 431,475,590 | 321,209,963 | ||||||
Income from operations | 88,432,162 | 35,145,967 | ||||||
Other (expense) income | ||||||||
Loss from equity method investments | (8,125,285) | (1,112,541) | ||||||
Interest expense | (560,515) | (79,689) | ||||||
Interest income | 1,258,638 | 1,015,204 | ||||||
Change in fair value of derivative instrument | - | (44,886) | ||||||
Gain on settlement of preexisting note receivable from ApolloMed | - | 921,938 | ||||||
Gain from investments – fair value adjustments | - | 13,697,018 | ||||||
Other income | 1,622,131 | 168,102 | ||||||
Total other (expense) income, net | (5,805,031) | 14,565,146 | ||||||
Income before provision for income taxes | 82,627,131 | 49,711,113 | ||||||
Provision for income taxes | 22,359,640 | 3,886,785 | ||||||
Net income | 60,267,491 | 45,824,328 | ||||||
Net income attributable to noncontrolling interests | 49,432,489 | 20,022,486 | ||||||
Net income attributable to Apollo Medical Holdings, Inc. | $ | 10,835,002 | $ | 25,801,842 | ||||
Earnings per share – basic | $ | 0.33 | $ | 1.01 | ||||
Earnings per share – diluted | $ | 0.29 | $ | 0.90 | ||||
Weighted average shares of common stock outstanding – basic | 32,893,940 | 25,525,786 | ||||||
Weighted average shares of common stock outstanding – diluted | 37,914,886 | 28,661,735 | ||||||
Note About Consolidated Entities
The Company consolidates entities in which it has a controlling financial interest. The Company consolidates subsidiaries in which it holds, directly or indirectly, more than 50% of the voting rights, and variable interest entities ("VIEs") in which the Company is the primary beneficiary. Noncontrolling interests represent equity ownership interests (including certain VIEs) in the Company's consolidated entities. The amount of net income attributable to noncontrolling interests is disclosed in the Company's consolidated statements of income.
Note About Stockholders' Equity, Certain Treasury Stock and Earnings Per Share
As of the date of this press release, 480,212 shares of ApolloMed's common stock to be issued as part of the merger (the "Merger") involving ApolloMed and Network Medical Management ("NMM") in 2017 are subject to ApolloMed receiving from those former NMM shareholders a properly completed letter of transmittal (and related exhibits) before such former NMM shareholders may receive their pro rata portion of ApolloMed common stock and warrants. Pending such receipt, such former NMM shareholders have the right to receive, without interest, their pro rata share of dividends or distributions with a record date after the effectiveness of the Merger. The Company's consolidated financial statements have treated such shares of common stock as outstanding, given the receipt of the letter of transmittal is considered perfunctory and the Company is legally obligated to issue these shares as of the closing of the Merger.
Shares of ApolloMed's common stock owned by Allied Physicians of California IPA (d.b.a. Allied Pacific of California IPA), a VIE of the Company, are legally issued and outstanding but excluded from shares of common stock outstanding in the Company's consolidated financial statements, as such shares are treated as treasury shares for accounting purposes. Such shares, therefore, are not included in the number of shares of common stock outstanding used to calculate the Company's earnings per share.
About Apollo Medical Holdings, Inc.
ApolloMed is a leading physician-centric integrated population health management company, which, together with its subsidiaries, including a Next Generation Accountable Care Organization ("NGACO"), and its affiliated independent practice associations ("IPAs") and management services organizations ("MSOs"), are working to provide coordinated, outcomes-based high-quality medical care for patients, particularly senior patients and patients with multiple chronic conditions, in a cost-effective manner. ApolloMed focuses on addressing the healthcare needs of its patients by leveraging its integrated health management and healthcare delivery platform that includes NMM (MSO), Apollo Medical Management (MSO), ApolloMed Hospitalists, APA ACO (NGACO), Allied Physicians of California (IPA) and Apollo Care Connect (Digital Population Health Management Platform). For more information, please visit www.apollomed.net.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, such as statements about the Company's continued growth, ability to delivery sustainable long-term value, ability to respond to the changing environment, operational focus, strategic growth plans, and merger integration efforts. Forward-looking statements reflect current views with respect to future events and financial performance and therefore cannot be guaranteed. Such statements are based on the current expectations and certain assumptions of the Company's management, and some or all of such expectations and assumptions may not materialize or may vary significantly from actual results. Actual results may also vary materially from forward-looking statements due to risks, uncertainties and other factors, known and unknown, including the risk factors described from time to time in the Company's reports to the SEC, including without limitation the risk factors discussed in the Company's Annual Report on Form 10-K filed with the SEC on March 18, 2019.
FOR MORE INFORMATION, PLEASE CONTACT:
Warren Hosseinion, M.D.
Co-Chief Executive Officer
Apollo Medical Holdings, Inc.
(818) 839-5200
[email protected]
View original content:http://www.prnewswire.com/news-releases/apollo-medical-holdings-reports-46-revenue-increase-for-2018-300814295.html
SOURCE Apollo Medical Holdings, Inc.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.